Mixed chimerism (MC) and secondary graft failure are frequent events following SCT for thalassemia. There is limited information regarding the outcome of donor lymphocyte infusion (DLI) to prevent rejection, mainly from case reports describing only successful cases. We describe a series of seven children affected by b-thalassemia treated with escalating doses of DLI for level 2-3 MC (donoro90%) following myeloablative SCT from a matched family donor. The infusions were safe and no acute or chronic GVHD were documented; five patients experienced neutropenia and thrombocytopenia resolving spontaneously. DLI was successful in converting to full donor chimerism two patients stratified in the low-risk class (Pesaro class II). Conversely, for five high-risk patients, DLI was not effective in preventing secondary graft failure. This limited series suggests that escalating doses of DLI are safe in thalassemia patients post myeloablative therapy but efficacy may be jeopardized by rapidly growing antidonor alloimmunity in high-risk patients. We suggest giving escalating doses of donor T cells to attempt a graft-versusthalassemia as soon as level 2-3 MC is detected.
Introduction
At present, SCT represents the only chance of cure for b-thalassemia major. 1 The most common cause of transplant failure is graft rejection, generally followed by autologous reconstitution. The presence of residual host haematopoietic cells observed after SCT is commonly referred to as mixed chimerism (MC), which is associated with an increased risk of subsequent graft failure and/or disease recurrence, particularly when the presence of residual host cells is higher than 25%. 2, 3 MC in thalassemia patients post-SCT can be classified according to the proportion of donor cells present in the recipient in MC level 1 (donor490%), MC level 2 (90%4donor475%) and MC level 3 (donoro75%). As recently confirmed, 4 although the risk of rejection in MC level 1 is low (only 1 out of 30 patients), it is higher (6 out of 13) in level 2-3 MC. There is no consensus on treatment of MC in these patients. A watch-and-wait approach leads to full graft rejection with relapse of transfusion-dependent thalassemia in the majority of patients, although cases of persistent and stable MC have been described. 3 In case of graft rejection, patients can be offered either conservative medical treatment or a second transplantation, balancing the risk of morbidity and mortality. 5 Alternatively, a modulation of the donor immune system can be attempted during MC either by escalating immunosuppression to decrease the host-versus-donor alloreactive potential or by increasing the donor-versus-host alloimmunity either by rapid discontinuation of immunosuppression priced by a higher risk of GVHD [6] [7] [8] or by infusion of immunocompetent donor cells. The use of donor lymphocytes infusion (DLI) has been well described to treat disease relapse for several haemato-oncologic disorders in adults [9] [10] [11] [12] [13] and in children [14] [15] [16] [17] such as chronic myeloid leukaemia, acute leukaemia, myelodysplasia, lymphoma, multiple myeloma, JMML and EBV associated lymphoproliferative disorders. Conversely, the experience with nonmalignant disease is limited, 18 only a few case reports are reported for haemoglobinopathies and probably only successes are described, usually associated with GVHD 19, 20 or GVHD and pancytopenia. 21 We describe a cohort of seven thalassemic children treated homogeneously with escalating doses of DLI following evidence of level 2-3 MC after myeloablative SCT, showing a good safety profile in all cases but efficacy only in low-risk patients.
Patients and methods

Definitions
MC is defined by the detection of 45% haematopoietic and/or immune cells of host origin post-SCT and is graded, as described earlier, 3 in level 1 (donor490%), level 2 (90%4donor475%) and level 3 (donoro75%). Adverse events are classified according to the National Cancer Institute common toxicity criteria. Poor graft function is defined as the development of a neutrophil count of o1 Â 10 9 /l (grade 4) and/or platelet count of o50 Â 10 9 /l (grade 3: 25-50 Â 10 9 /l, grade 4: o25 Â 10 9 /l).
Patients' characteristics and transplant procedures Patients' and donors' characteristics potentially significant for the outcome of DLI are summarized in Table 1 23 and CY 50 mg/kg daily on days À5, À4, À3, À2 (total dose 200 mg/kg). Patient #5, who was transplanted from a phenotypically identical mother, also received rabbit anti-thymocyte globulin (Thymoglobuline; Genzyme-Sangstat, Lyon, France) at 2.5 mg/kg once daily i.v. on days À5, À4, À3 (total dose 7.5 mg/kg). Patients in class III (#1, #2, #3, #4) were conditioned with i.v. BU and CY 40 mg/kg daily on days À5, À4, À3, À2 (total dose 160 mg/kg) preceded by a 'pre-conditioning' 24 based on azathioprine, hydroxyurea and fludarabine (Flu) 20 mg/m 2 on days À17, À16, À15, À14, À13 (total dose 100 mg/m 2 ). Following a high incidence of rejection in the first patients stratified as class III, children #3 and #4 received an intensified immunosuppression with a higher dose of Flu in the pre-conditioning regimen (150 mg/m 2 ) and Thymoglobuline 2.5 mg/kg once daily on days À7, À6, À5 (total dose 7.5 mg/kg). For prophylaxis against GVHD patients received methylprednisolone 0.5 mg/kg from day À1 until day 25 and CyA, at a dose that was adjusted to achieve a plasma concentration of 150-250 ng/ml. In the absence of GVHD, the dose of CyA was tapered from day 60 until discontinuation at 1 year. In case of CyA toxicity, patients were switched to tacrolimus (FK506) to achieve a plasma concentration of 5-15 ng/ml (patient #6, #7). All patients received a short course of i.v. Methotrexate 10 mg/m2 on day 1, 3 and 6. CMV antigenemia was monitored by pp65 antigen in PBMCs and by CMVDNA quantitative PCR. Written informed consent was obtained from patients' parents or legal guardians in each case, with the collaboration of a translator fluent in both Italian and the subjects' spoken language.
Chimerism monitoring
Chimerism was monitored at 30, 60, 90, 120 and 365 days following SCT. The percentage of donor/recipient DNA was evaluated using PCR-based analysis of selected polymorphic STRs loci. Chimerism was assessed on BM, peripheral blood (PB) and subpopulations sorted from PB for the CD3 subset by magnetic beads coupled with the appropriate specific antibodies (Miltenyi Biotec, Anburn, CA, USA).
DLI schedule Criteria for DLI was MC level 2-3 (donor chimerism o90%) confirmed on two consecutive occasions following myeloablative SCT for b-thalassemia and absence of GVHD at the time of infusion. The percentage of donor CD3 cells was recorded but not used as a cut off for intervention because the algorithm defining the risk of rejection was developed on whole marrow chimerism. Marrow donors were evaluated for their eligibility to donate DLI by haematological, biochemical and virological analysis according to the Italian law within 7 days from lymphocytes donations. Donor lymphocytes were obtained by leukapheresis in 1 session or phlebotomy. The latter was performed in case of AB0 compatibility and only when judged feasible based on the donor/recipient weight and 12 to reduce the risk of GVHD as compared with a bulk-dose DLI approach. Patients transplanted from a sibling donor (N ¼ 6) received a first dose of 1 Â 10 7 CD3/ kg and, in the absence of side effects, conversion to full donor chimerism or rejection, a second dose of 5 Â 10 7 CD3/kg was given at least at 5-week interval from the first dose. The patient transplanted from a phenotypically identical marrow was dealt as an alternative donor and received a first dose of 1 Â 10 6 CD3/kg and was scheduled for a second dose of 1 Â 10 7 CD3/kg as specified above. Immunosuppressive treatment was continued with the standard schedule of slow tapering to a complete stop at 1-year post-SCT. This decision was based on the balance between the risk of reduced efficacy of DLI (an approach of unknown efficacy) during immunosoppressive treatment, and the increased risk of GVHD by abrupt discontinuation, which is not beneficial in this non-oncological setting. In addition, prompt withdrawal of immunosuppression could induce rapid graft rejection. Patients were followed-up weekly after DLI for side effects or GVHD and evaluated monthly for donor chimerism.
Results
Safety
Seven patients were treated with DLI for level 2 (N ¼ 1) or level 3 (N ¼ 6) MC following SCT for thalassemia. A total of 11 infusions were given. Median time between SCT and DLI was 167 days (range, 90-267 days) and between first and second DLI 67 days (range, 39-86 days). No immediate adverse effect occurred. All patients were evaluable for graft function and GVHD. None of the patients presented any sign of acute or chronic GVHD. Cytopenia after DLI occurred in five patients: grade 4 neutropenia was observed in five patients (pt #2, #3, #4, #5, #7) at a median time of 65 days after the first DLI (range, 10-100 days) and followed by spontaneous resolution in the absence of infectious episodes. Two patients experienced grade 3-4 thrombocytopenia: patient #3 had transient grade 3 thrombocytopenia (nadir: 32 Â 10 9 /l) 17 days from the second DLI (chimerism at DLI 25% donor), whereas patient #4 presented a transient grade 4 thrombocytopenia (nadir: 10 Â 10 9 /l) 63 days from the second dose (chimerism at DLI 60% donor). Thrombocytopenia did not result in any haemorrhagic episode and resolved spontaneously; both patients converted to full host chimerism. CMV reactivation did not occur in any of the patients receiving DLI. All patients are alive at a median follow-up of 271 days (range, 92-762 days) after the last DLI.
Efficacy
Outcome was different between low-risk class II patients (N ¼ 2) and children affected by high-risk class III thalassemia (N ¼ 4) or undergoing a phenotypically identical SCT (N ¼ 1) (Table 1) . DLI was effective in converting to full donor chimerism the two patients belonging to the low-risk class. Patient #6 was infused with a first dose of 1 Â 10 7 CD3/kg on day 90 (transfusion independent; chimerism pre-DLI on BM 65% donor, on CD3 þ cells 40% donor) and with a second dose of 5 Â 10 7 CD3/kg on day 176 (transfusion independent; chimerism pre-DLI on BM 50%, on CD3 þ cells 60% donor). Following a gap in the follow-up, on day 480 a conversion to 100% donor chimerism was observed. The patient remains well, transfusion independent and full donor at 2.5 years after SCT. Patient #7 received one dose of DLI of 1 Â 10 7 CD3/ kg on day 174 (chimerism on BM 82%, on CD3 þ cells 90% donor). At the time of DLI, the patient was transfusion dependent requiring 1 unit of red blood cells every 3 weeks to a cut off of 70 g/l Hb (total of 7 transfusions post-SCT). One month later, the patient converted to 100% donor becoming transfusion independent. The patient remains well and transfusion free 18 months post-SCT (Figure 1 ). Differently from low-risk patients, DLI was never successful in preventing rejection in class III (N ¼ 4) and in the phenotypically identical SCT (N ¼ 1) (Figure 2 ). All the patients treated with DLI were transfusion dependent at the time of treatment with a transfusion requirement between every 2 to every 5 weeks. The first DLI was performed after a median of 167 days from SCT (range, 106-267 days). Four patients were treated in MC level 3, one patient (#4) in MC level 2 (85% donor), though CD3 þ donor T cells were only 70%. A second DLI was performed in three patients at 175, 329 and 306 days post-SCT. All patients experienced complete graft rejection with full host haematopoietic recovery.
Discussion
Few case reports describe successful treatment of MC with DLI following SCT for haemoglobinopathies [19] [20] [21] but negative results are probably under-reported. The efficacy of DLI is unclear as compared with settings of clear benefit such as CML. 12, 13 We report the first series ever described of thalassemic patients treated with DLI for the prevention of graft rejection. Our cohort was treated with a homogeneous protocol of escalating doses of donor lymphocytes when level 2-3 MC was detected. A cut off for intervention was set at level 2 MC balancing the risk of DLI with the risk of rejection, which is nearly 50% 4 in patients with level 2-3 MC. The procedure was safe and none of the patients experienced acute or chronic GVHD. The absence of GVHD can be explained by several reasons. The application of an escalating dose regimen protects from GVHD compared with a bulk dose regimen. 12 Moreover, the second infusion always proceeded after at least 5 weeks observation from the first dose. In addition, patients were still receiving CyA at the time of DLI and this may have protected from GVHD. Finally, the incidence of GVHD is reduced when patients are infused when mixed chimeras.
We experienced a high incidence of cytopenia (5 out of 7 patients) in the absence of infective or haemorrhagic episode with a spontaneous resolution. In a heterogeneous cohort of 140 patients treated with DLI, the incidence of pancytopenia was 20%. 9 Pancytopenia post-DLI is thought to be due to the ablation of recipient cells by DLI and concomitant inadequacy of donor stem cells to recovery haematopoiesis. 26 The risk of pancytopenia is related to the stage of the disease at DLI as shown by a higher incidence in CML patients in haematological relapse than in molecular/cytogenetic relapse. 27 Similarly, the higher the degree of host chimerism, the higher the risk of pancytopenia as shown by results of DLI following reduced intensity conditioning. 28 Although our series is small, we could confirm that pancytopenia occurred in patients with the smallest fraction of donor haematopoiesis. Therefore, although both GVHD and pancytopenia are expression of anti-donor immunity, their risk factors are different resulting in high incidence of pancytopenia and absence of GVHD in our series. Two patients in the low transplant risk group converted to full donor chimerism, whereas all the high-risk patients had secondary donor graft rejection. Class II patients are known to have better outcome following SCT due to better medical conditions and less alloimmunization following a reduced exposure to allogeneic blood products. Therefore possibly a coexistence of host and donor haematopoietic cells is tolerated longer allowing time to DLI to eliminate residual host haemopoiesis. Furthermore, because in vivo expansion of transfused T cells is not likely to occur before 3-4 weeks from infusion, rapidly evolving anti-donor T cells in high-risk patients could proliferate and progress to over rejection before infused donor T cells induce a graft-versus-thalassemia effect. Notably, the two patients responding to DLI were receiving tacrolimus as immunosuppressive agent due to CyA toxicity. Although no data are available for SCT, in the context of solid organ transplantation some reports suggest that tacrolimus can rescue from incipient allograft rejection. 29 It remains uncertain whether tacrolimus may have contributed to this different outcome.
On the basis of these results, we suggest that immunotherapy with DLI is an option for MC following SCT for thalassemia, especially for low-risk patients. To increase the chances of success, chimerism post-SCT should be followed-up closely and, on evidence of level 2-3 MC, escalating doses of donor lymphocytes should be given promptly. 
